Radiation resistance in cancer therapy: Meeting summary and research opportunities report of an NCI workshop held september 13, 2010

Radiation Research

Volumn 176, Issue 3, 2011, Pages

  Glazer, Peter M ^a   Grandis, Jennifer ^b   Powell, Simon N ^c   Brown, J Martin ^d   Helleday, Thomas ^e   Bristow, Robert ^f   Powis, Garth ^g   Hill, Richard P ^f   Le, Quynh Thu ^d   Pelroy, Richard ^h   Mohla, Suresh ^h   Bernhard, Eric J ^h  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CUSTIRSEN; DNA POLYMERASE; DNA POLYMERASE THETA; NELFINAVIR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; RAD52 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR AGONIST; TOLL LIKE RECEPTOR AGONIST 8 AGONIST; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; HUMAN; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

HUMANS; NEOPLASMS; RADIATION TOLERANCE;

EID: 80052146090     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RROL02.1     Document Type: Article

References (8)

1. Barker CA, Powell SN. Enhancing radiotherapy through a greater understanding of homologous recombination. Semin Radiat Oncol 2010; 20:267-73 e3.
2. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010; 120:694-705.
3. Evers B, Helleday T, Jonkers J. Targeting homologous recombination repair defects in cancer. Trends Pharmacol Sci 2010; 31:372-80.
4. Ishkanian AS, Zafarana G, Thoms J, Bristow RG. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. Acta Oncol 2010; 49:888-94.
5. Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer PM. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci USA 2010; 107:2201-6.
6. Schwartz DL, Bankson JA, Lemos R, Jr., Lai SY, Thittai AK, He Y, et al. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther 2010; 9:2057-67.
7. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008; 8:545-54. (Pubitemid 351881850)
8. Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010; 28:2989-95.